FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Revised BA/BE Sample Handling Guidance

FDA issues a revised final and draft guidance on the handling and retention of BA and BE testing samples.

latest-news-card-1
Human Drugs

Bioresearch Monitoring Issues at New York Site

FDA warns Dr. Bret Rutherford about violations in his work as a clinical study investigator at the New York State Psychiatric Institute.

latest-news-card-1
Biologics

Mesoblast Refiling BLA for Remestemcel-L

Mesoblast says it will refile its BLA for remestemcel-L for treating pediatric steroid-refractory acute graft versus host disease following favorable...

latest-news-card-1
Human Drugs

FDA Warns Against Topical OTC Analgesics

FDA issues a warning to not use certain over-the-counter analgesic products that are marketed for topical use to relieve pain before, during or after ...

latest-news-card-1
Federal Register

PARP Inhibitor Ovarian Cancer Indications Withdrawn

Federal Register notice: FDA announces that it is withdrawing approval of the indications for treating adult patients with advanced ovarian cancer for...

latest-news-card-1
Human Drugs

Quantitative Medicine Center of Excellence Created

CDER creates a new Center of Excellence for Quantitative Medicine to advance therapeutic medical product development and inform regulatory decision-ma...

latest-news-card-1
Federal Register

4 Information Collections Approved by OMB

FDA posts a notification about four information collections that have been approved by OMB.

latest-news-card-1
Medical Devices

Medline Recalls Kits/Tray Over Sterility

Medline Industries recalls certain kits, trays and packs in direct response to Nurse Assists 11/2023 recall of 0.9% sodium chloride irrigation USP and...

latest-news-card-1
Human Drugs

J&Js Opsynvi OKd for Pulmonary Hypertension

FDA approves Johnson & Johnsons Opsynvi, a combination single tablet of macitentan and tadalafil for treating adults with pulmonary arterial hypertens...

latest-news-card-1
Biologics

Regeneron Complete Response on Lymphoma BLA

FDA sends Regeneron Pharmaceuticals two complete response letters on its BLA for odronextamab in relapsed/refractory follicular lymphoma and in R/R di...